Interim Analysis of ZUMA-12: A Phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients with High-Risk Large B Cell Lymphoma (LBCL).

ZUMA-12 is the first study evaluating CAR T therapy first-line in high-risk LBCL. The results demonstrated an ORR of 85% and a CR in 74% of patients treated with Axi-Cel. At data cut-off 70% of patients had ongoing responses. Continued follow-up will assess durability of response which, if confirmed, supports the concept that early use of cellular therapies in high risk patients may be a pathway to improved outcomes over chemotherapy.